Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM.
Khattak MA, et al.
Eur J Cancer. 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3.
Eur J Cancer. 2022.
PMID: 36202690
Free article.
Clinical Trial.